Cambridge Investment Research Advisors
ROIV icon

Cambridge Investment Research Advisors’s Roivant Sciences ROIV Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$368K Buy
10,398
+227
+2% +$6.71K ﹤0.01% 3256
2026
Q1 		$282K Sell
10,171
-2,581
-20% -$66.3K ﹤0.01% 3341
2025
Q4 		$277K Buy
12,752
+848
+7% +$16.7K ﹤0.01% 3278
2025
Q3 		$180K Sell
11,904
-3,996
-25% -$49.5K ﹤0.01% 3508
2025
Q2 		$179K Sell
15,900
-30,127
-65% -$327K ﹤0.01% 3373
2025
Q1 		$464K Sell
46,027
-1,741
-4% -$18.8K ﹤0.01% 2520
2024
Q4 		$565K Buy
47,768
+5,616
+13% +$66.4K ﹤0.01% 2327
2024
Q3 		$486K Sell
42,152
-19,640
-32% -$224K ﹤0.01% 2442
2024
Q2 		$653K Buy
61,792
+5,798
+10% +$63.5K ﹤0.01% 2077
2024
Q1 		$590K Buy
+55,994
New +$604K ﹤0.01% 2149

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Cambridge Investment Research Advisors's ROIV Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Roivant Sciences (ROIV) stake by 2.2% in Q2 2026, buying an estimated $6.71K and bringing the position to 10,398 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #3256.

Cambridge Investment Research Advisors first reported a position in ROIV in Q1 2024 and has held it in 10 quarters since. The position peaked at $653K in Q2 2024. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Cambridge Investment Research Advisors held 10,398 shares of Roivant Sciences worth $368K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 227 Roivant Sciences shares in Q2 2026, an estimated $6.71K.
  • Roivant Sciences made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3256 holding.
  • Cambridge Investment Research Advisors first reported a position in Roivant Sciences in Q1 2024 and has held it in 10 quarters since.
  • Cambridge Investment Research Advisors's Roivant Sciences position peaked at $653K in Q2 2024.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.